Acute effect of XXXX administration on baroreflex sensitivity in @entity1 with @entity583 .

@entity1 @entity712 @entity308 @entity101 @entity6 @entity3371 @entity4375 @entity2647 @entity583
@entity308 ( @entity4375 ) after @entity583 ( @entity583 ) is considered an indication of decreased vagal and/or increased sympathetic tone. To determine the effect of angiotensin converting enzyme inhibitors (ACEI) on @entity4375 after @entity583 we studied 27 @entity1 with a first Q wave @entity583 , no signs of @entity712 and no history of arterial @entity101 or @entity6 . An additional group of 10 @entity1 with the same clinical characteristics served as controls. On the 5th day after the onset of @entity583 , three consecutive boluses of @entity2647 were given intravenously and baseline @entity4375 was taken as the mean slope of the linear regression lines of RR intervals over systolic blood pressure. QT interval was also measured and corrected according to Bazett's formula (QTc). Consequently, a single oral dose of @entity3371 50 mg or placebo was given to treatment or control group @entity1 , respectively; @entity4375 and QTc were reassessed 1 h later. One hour after @entity3371 administration @entity4375 increased from 5.95 +/- 2.80 to 9.14 +/- 3.46 ms.mmHg-1 (P < 0.0001); QTc increased from 414 +/- 46 to 425 +/- 46 ms (P < 0.0001), systolic blood pressure decreased from 125 +/- 19 to 115 +/- 15 mmHg (P = 0.0002), while heart rate did not change significantly. Baseline @entity4375 was correlated only with age (r = -0.74, P < 0.0001). In the control group, 1 h after placebo, no difference was observed in any variable compared to baseline. @entity3371 appears to improve @entity4375 immediately in the early phase of @entity583 .
